ORAMED PHARMACEUTICALS INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate
ORAMED PHARMACEUTICALS INC. (ORMP) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate of 52.87% for the 1-month period ending 2022-09-18, per its 10-Q filed 2022-11-10.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate · last filed 2023-03-06
- ORAMED PHARMACEUTICALS INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2015-11-30 was 80.49%.
- ORAMED PHARMACEUTICALS INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2014 was 82.06%.
- ORAMED PHARMACEUTICALS INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2012 was 76.03%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 0 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 0 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 1 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 12 month |
|---|---|---|---|---|---|---|---|
| 2022-09-18 | 52.87% 10-Q · filed 2022-11-10 | ||||||
| 2022-05-02 | 65.26% 10-Q · filed 2022-11-10 | ||||||
| 2022-01-03 | 63.22% 10-Q · filed 2022-11-10 | ||||||
| 2021-08-04 | 61.98% 10-K · filed 2023-03-06 | ||||||
| 2021-02-17 | 64.39% 10-K · filed 2023-03-06 | ||||||
| 2021-02-03 | 61.07% 10-K · filed 2023-03-06 | ||||||
| 2020-01-08 | 62.55% 10-K · filed 2021-11-24 | 67.87% 10-K · filed 2020-11-24 | |||||
| 2016-05-31 | 79.48% 10-Q · filed 2016-07-06 | ||||||
| 2016-02-29 | 79.74% 10-Q · filed 2016-04-06 | ||||||
| 2015-11-30 | 80.49% 10-Q · filed 2016-01-13 | ||||||
| 2014-08-31 | 82.06% 10-K · filed 2014-11-14 | ||||||
| 2012-08-31 | 76.03% 10-K · filed 2014-11-14 | ||||||
| 2011-07-31 | 113.50% 10-K · filed 2012-12-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B |